What is Ryght?
Ryght operates at the intersection of artificial intelligence and clinical research, providing an agentic-AI platform that automates critical stages of the trial lifecycle, including site selection, activation, and patient enrollment. By integrating generative-AI agents with a secure digital-twin network encompassing over 100,000 trial sites, the company offers a robust service-as-software solution. This infrastructure is built to meet stringent SOC 2 compliance standards, ensuring that sponsors, contract research organizations (CROs), and research sites can operate with high levels of data security and operational efficiency. Ryght's core value proposition lies in its ability to reduce trial costs while simultaneously improving patient access to life-saving therapies.
How much funding has Ryght raised?
Ryght has raised a total of $30M across 1 funding round:
Seed
$30M
Seed (2025): $30M with participation from Virtu Venture, Page One Ventures, AIX Ventures, Iaso Ventures, and Top Harvest Capital
Key Investors in Ryght
AIX Ventures
AIX Ventures is a venture capital firm focused on investing in seed stage AI startups and partnering with top AI practitioners to transform industries.
Iaso Ventures
Iaso Ventures is dedicated to catalyzing biodigital innovation in next-generation life sciences, investing in transformative startups focused on curing diseases.
Top Harvest Capital
Top Harvest Capital is a venture capital firm that invests in early-stage AI startups within the technology and healthcare sectors, founded by experienced professionals from Google Ventures.
What's next for Ryght?
With this major strategic investment, Ryght is poised to deepen its penetration into the enterprise healthcare market. The company's forward-looking strategy focuses on scaling its digital-twin network and refining its AI-driven automation tools to address the persistent bottlenecks in clinical trial execution. As the industry continues to demand faster, more cost-effective research methodologies, Ryght's platform is well-positioned to become a standard utility for global pharmaceutical sponsors. Future growth will likely involve expanding the platform's capabilities to support more complex therapeutic areas and strengthening partnerships with key stakeholders in the clinical research value chain.
See full Ryght company page
